low estrogen [fndg]
Endometrial Cancer [neop]
case control [hlca]
Study [mnob]
urogenital [bdsy]
symptoms [ftcn]
postmenopausal [tmco]
Women [popg]
symptoms [ftcn]
low estrogen [fndg]
Formulation [resa]
Administered [ftcn]
Orally [spco]
low estrogen [fndg]
Formulation [resa]
Assumed [inpr]
Few [qnco]
adverse effects [ftcn]
Endometrium [bpoc]
Endometrial [spco]
Neoplasia [neop]
Quantify [qnco]
Methods [inpr]
Population Based Study [resa]
case control [hlca]
Sweden [geoa]
Endometrial Cancer [neop]
postmenopausal [tmco]
Women [popg]
Obtained [ftcn]
Detailed [qlco]
Information [idcn]
hormone replacement [topp]
Cases [ftcn]
Endometrial Cancer [neop]
Population Controls [ocdi]
histopathology [ftcn]
Cases [ftcn]
Reclassified [qlco]
Endometrial Hyperplasia [dsyn]
Atypical [qlco]
Odds Ratios [qnco]
Cl - [elii]
Calculated [ftcn]
Unconditional [idcn]
Logistic Regression [resa]
findings [ftcn]
Adjustment [inbe]
Oral use [ftcn]
Estriol 2 MG [clnd]
Daily [tmco]
Increased [qnco]
Relative Risk [qnco]
Endometrial Cancer [neop]
Endometrial Hyperplasia [dsyn]
Atypical [qlco]
Odds Ratios [qnco]
Compared [acty]
Never [tmco]
cl-2 [gngm]
Association [menp]
Strong [qlco]
Well Differentiated [qlco]
Limited [ftcn]
Invasion [fndg]
Excess [qlco]
Relative Risk [qnco]
Lost [ftcn]
Rapidly [qlco]
Cessation [acty]
treatment [ftcn]
Weak [sosy]
Associations [menp]
Observed [ftcn]
Vaginal [bpoc]
Application [hlca]
low estrogen [fndg]
Formulation [resa]
Relative Risk [qnco]
Endometrial [spco]
Neoplasia [neop]
Interpretation [inpr]
Oral [spco]
Vaginal [bpoc]
treatment [ftcn]
low estrogen [fndg]
Formulation [resa]
Relative Risk [qnco]
Endometrial [spco]
Neoplasia [neop]
Close [ftcn]
surveillance [ftcn]
Patients [podg]
Needed [qlco]
Addition [ftcn]
Progestagen [horm, phsu, strd]
considered [idcn]
